Oral Contraceptive Options for Women Taking Levetiracetam (Keppra)
This 37-year-old woman with epilepsy taking levetiracetam can safely use any standard combined oral contraceptive or progestin-only contraceptive without concern for drug interactions or reduced contraceptive efficacy.
Why Levetiracetam is Contraceptive-Friendly
Levetiracetam is a non-enzyme-inducing antiepileptic drug that does not interact with hormonal contraceptives. The FDA drug label for Keppra explicitly states that levetiracetam (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely 1. Reciprocally, the oral contraceptive did not affect levetiracetam levels 1.
This bidirectional lack of interaction has been confirmed in clinical studies showing no effect on levetiracetam clearance in women using oral contraceptives 2.
Recommended Contraceptive Options
First-Line Choices:
- Any standard combined oral contraceptive (COC) containing ethinyl estradiol (20-35 mcg) plus any progestin
- Progestin-only pills (POPs) - traditional or drospirenone formulations
- Contraceptive patch or vaginal ring (combined hormonal methods)
Additional Highly Effective Options:
- Depot medroxyprogesterone acetate (DMPA) injection
- Etonogestrel implant
- Levonorgestrel or copper IUD
All of these methods are classified as Category 1 (no restriction for use) for women taking levetiracetam according to U.S. Medical Eligibility Criteria 3.
Critical Distinction from Enzyme-Inducing Antiepileptics
The U.S. Medical Eligibility Criteria explicitly differentiates levetiracetam from problematic antiepileptics. Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine) are Category 3 for progestin-only pills and implants due to reduced contraceptive effectiveness 3. However, lamotrigine and levetiracetam are Category 1 - meaning no drug interactions occur 3.
Age-Specific Considerations for This Patient
At 37 years old, this patient requires additional assessment before prescribing combined hormonal contraceptives:
Required Pre-Prescription Evaluation:
- Blood pressure measurement (mandatory before any COC initiation) 4
- Smoking status - combined contraception is contraindicated in smokers ≥35 years, especially if >15 cigarettes/day 5
- Cardiovascular risk factors - hypertension, diabetes, migraine with aura, or history of thromboembolism would contraindicate COCs 5
If COCs are Contraindicated:
Progestin-only methods become preferred:
- Progestin-only pills (norethindrone, norgestrel, or drospirenone formulations)
- DMPA injection (Category 1 regardless of cardiovascular risk factors)
- Etonogestrel implant
- Levonorgestrel IUD
These progestin-only options have no estrogen-related cardiovascular risks and maintain full efficacy with levetiracetam 3.
Practical Prescribing Algorithm
Step 1: Measure blood pressure and assess cardiovascular risk factors
Step 2: If blood pressure normal and no cardiovascular contraindications:
- Prescribe any standard COC (e.g., 30-35 mcg ethinyl estradiol + levonorgestrel/norgestimate/drospirenone)
- No dose adjustment needed
- No backup contraception required if started within 5 days of menses 4
Step 3: If cardiovascular contraindications exist:
- Choose progestin-only method (POP, DMPA, implant, or LNG-IUD)
- Counsel that levetiracetam does not reduce effectiveness of any of these options
Step 4: Counsel patient:
- Levetiracetam will not reduce contraceptive effectiveness
- Contraceptive will not affect seizure control or levetiracetam levels
- No special monitoring required beyond routine contraceptive follow-up
Common Pitfalls to Avoid
Do not confuse levetiracetam with enzyme-inducing antiepileptics. Many clinicians inappropriately recommend higher-dose contraceptives (50 mcg ethinyl estradiol) or avoid hormonal contraception entirely in women taking levetiracetam, based on outdated concerns about enzyme-inducing drugs. This is unnecessary and may expose patients to higher estrogen doses with increased thrombotic risk 6, 7.
Do not overlook age-related cardiovascular screening. While levetiracetam poses no contraceptive interaction concerns, this 37-year-old woman still requires standard cardiovascular risk assessment before COC initiation, particularly given her aspirin use (which may indicate cardiovascular risk factors) 5, 8.
Consider medication list implications. Her aspirin 81 mg suggests possible cardiovascular history or risk factors that warrant investigation before prescribing estrogen-containing contraceptives 8.